Loading
A phase 3 trial of Florastamin F-18 run by FutureChem, active.
Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis is a phase 3 interventional study registered as NCT05004285 by FutureChem, with 398 participants planned, started 2021-04-28. Conditions listed: High Risk Prostate Carcinoma. No results are recorded here; the registry entry is the source.
Shares FutureChem, Florastamin F-18, Prostate cancer.
Shares Florastamin F-18, Prostate cancer.